Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis - PubMed
3 hours ago
- #Pruritus
- #Primary Biliary Cholangitis
- #PPAR agonists
- PPAR agonists, including bezafibrate and seladelpar, significantly reduce pruritus severity in primary biliary cholangitis (PBC) patients with moderate-to-severe symptoms.
- The meta-analysis found improvements in itch-specific outcomes (NRS scores) at 3, 6, and 12 months, but effects on overall health-related quality of life (HRQoL) remain uncertain.
- Five randomized controlled trials (RCTs) involving 660 patients were included, with 390 receiving PPAR agonists and 270 on placebo.
- The study highlights the need for validated, symptom-focused endpoints in future PBC trials to better assess treatment efficacy.